3,8-Diazabicyclo[3.2.1]octan-2-one peptide mimetics: Synthesis of a conformationally restricted inhibitor of farnesyltransferase

Organic Letters

Volumn 3, Issue 6, 2001, Pages 865-868

  Dinsmore, Christopher J ^a   Bergman, Jeffrey M ^a   Bogusky, Michael J ^a   Culberson, J Christopher ^a   Hamilton, Kelly A ^a   Graham, Samuel L ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,8 DIAZABICYCLO(3.2.1)OCTAN 2 ONE; 3,8-DIAZABICYCLO(3.2.1)OCTAN-2-ONE; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; ENZYME INHIBITOR; FARNESYL TRANS TRANSFERASE; FUSED HETEROCYCLIC RINGS; PEPTIDE; TRANSFERASE;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; DRUG ANTAGONISM; SYNTHESIS; THERMODYNAMICS;

ALKYL AND ARYL TRANSFERASES; BICYCLO COMPOUNDS, HETEROCYCLIC; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; INDICATORS AND REAGENTS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; PEPTIDES; THERMODYNAMICS;

EID: 0035932606     PISSN: 15237060     EISSN: None     Source Type: Journal    
DOI: 10.1021/ol015504w     Document Type: Article

References (44)

1. Recent reviews: (a) Hanessian, S.; McNaughton-Smith, G.; Lombart, H.-G.; Lubell, W. D. Tetrahedron 1997, 53, 12789.
2. (b) Liskamp, R. M. J. Recl. Trav. Chim. Pays-Bas 1994, 113, 1.
3. (c) Gante, J. Angew. Chem., Int. Ed. Engl. 1994, 33, 1699.
4. (d) Adang, A. E. P.; Hermkens, P. H. H.; Linders, J. T. M.; Ottenheijm, H. C. J.; van Staveren, C. J. Recl. Trav. Chim. Pays-Bas 1994, 113, 63.
5. (e) Giannis, A.; Kolter, T. Angew. Chem., Int. Ed. Engl. 1993, 32, 1244.
6. Freidinger, R. M.; Veber, D. F.; Perlow, D. S.; Brooke, J. R.; Saperstein, R. Science 1980, 210, 656.
7. (a) DiMaio, J.; Belleau, B. J. Chem. Soc., Perkin Trans. 1 1989, 1687.
8. (b) Kolter, T.; Dahl, C.; Giannis, A. Liebigs Ann. 1995, 625.
9. (a) Hoffman, R. W. Angew. Chem., Int. Ed. Engl. 1992, 31, 1124 and references therein.
10. (b) N-Sugg, E. E.; Griffin, J. F.; Portoghese, P. S. J. Org. Chem. 1985, 50, 5032.
11. (a) Jain, S.; Sujatha, K.; Krishna, K. V. R.; Roy, R.; Singh, J.; Anand, N. Tetrahedron 1992, 48, 4985.
12. (b) Sturm, P. A.; Henry, D. W. J. Med. Chem. 1974, 17, 481.
13. (c) Cignarella, G.; Testa, E. Farmaco. Ed. Sci. 1969, 24, 419.
14. (d) Blackman, S. W.; Baltzly, R. J. Org. Chem. 1961, 26, 2750.
15. (e) Cignarella, G.; Nathansohn, G. J. Org. Chem. 1961, 26, 2747.
16. (f) Cignarella, G.; Nathansohn, G. J. Org. Chem. 1961, 26, 1500.
17. (a) Schanen, V.; Riche, C.; Chiaroni, A.; Quiron, J.-C.; Husson, H.-P. Tetrahedron Lett. 1994, 35, 2533.
18. (b) Pohlmann, A.; Schanen, V.; Guillaume, D.; Quirion, J.-C.; Husson, H.-P. J. Org. Chem. 1997, 62, 1016.
19. (c) Bhatt, U.; Mohamed, N.; Just, G.; Roberts, E. Tetrahedron Lett. 1997, 38, 3679.
20. (d) Weissman, S. A.; Lewis (nee Scull), S.; Askin, D.; Volante, R. P.; Reider, P. J. Tetrahedron Lett. 1998, 39, 7459.
21. (e) Dinsmore, C. J.; Zartman, C. B. Tetrahedron Lett. 2000, 41, 6309.
22. Hart, B. P.; Rapoport, H. J. Org. Chem. 1999, 64, 2050.
23. Goel, O. P.; Krolls, U.; Stier, M.; Kesten, S. Org. Synth. 1988, 67, 69.
24. 3N, DMF), and HPLC analysis to confirm ≥ 97% enantiomer purity.
25. Transannular alkylation of the methanesulfonate i under the same conditions provided an 8:1 mixture of 9a and the alcohol derived from cleavage of the methanesulfonyl group. Attempts to cyclize the sulfonium salt ii derived from L-methionine were unsuccessful. matrix presented
26. Gibson (nee Thomas), S. E.; Guillo, N.; Tozer, M. J. Tetrahedron 1999, 55, 585.
27. Attempted cyclization using LiHMDS (THF, -78 to 0°C, 5 h) gave only recovered 11. The use of KHMDS under the same conditions resulted in gradual conversion to the dihydrooxazinone iii. matrix presented
28. (a) Kato, K.; Cox, A. D.; Hisaka, M. M.; Graham, S. M.; Buss, J. E. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 6403.
29. (b) Rowinsky, E. K.; Windle, J. L.; Von Hoff, D. D. J. Clin. Oncol. 1999, 17, 3631.
30. (a) Oliff, A. Biochim. Biophys. Acta 1999, 1423, C19.
31. (b) End, D. W. Invest. New Drugs 1999, 17, 241.
32. (c) Gibbs, J. B. J. Clin. Invest. 2000, 105, 9.
33. (a) Williams, T. M.; Dinsmore, C. J.; Bergman, J. M.; Hutchinson, J. H.; MacTough, S. C.; Stump, C. S.; Wei, D. D.; Zartman, C. B.; Bogusky, M. J.; Chen, I.-W.; Culberson, J. C.; Koblan, K. S.; Kohl, N. E.; Lobell, R. B.; Motzel, S. L.; Salata, J. J.; Gibbs, J. B.; Graham, S. L.; Hartman, G. D.; Oliff, A. I.; Huff, J. R. 216th National Meeting of the American Chemical Society, Boston, MA, 1998; American Chemical Society: Washington, DC, 1998; MEDI 309.
34. (b) manuscript in preparation.
35. Dinsmore, C. J.; Bogusky, M. J.; Culberson, J. C.; Bergman, J. M.; Homnick, C. F.; Zartman, C. B.; Mosser, S. D.; Schaber, M. D.; Robinson, R. G.; Koblan, K. S.; Huber, H. E.; Graham, S. L.; Hartman, G. D.; Huff, J. R.; Williams, T. M. J. Am. Chem. Soc. 2001, 123, in press.
36. Dinsmore, C. J.; Bergman, J. M.; Wei, D. D.; Zartman, C. B.; Davide, J. P.; Greenberg, I. B.; Liu, D.; O'Neill, T. J.; Gibbs, J. B.; Koblan, K. S.; Kohl, N. E.; Lobell, R. B.; Chen, I.-W.; McLoughlin, D. A.; Olah, T. V.; Graham, S. L.; Hartman, G. D.; Williams, T. M. Bioorg. Med. Chem. Lett. 2001, 11, 537.
37. (a) Schlessinger, R. H.; Bebernitz, G. R.; Lin, P.; Poss, A. Y. J. Am. Chem. Soc. 1985, 107, 1777.
38. (b) DeShong, P.; Ramesh, S.; Elango, V.; Perez, J. J. J. Am. Chem. Soc. 1985, 107, 5219.
39. Dinsmore, C. J.; Zartman, C. B. Tetrahedron Lett. 1999, 40, 3989.
40. (a) Molecular modeling: Conformations were generated using metric matrix distance geometry algorithm JG (S. Kearsley, Merck & Co., Inc., unpublished). The structures were subjected to energy minimization within Macromodel (ref 20b) using the MMFF force field.
41. (b) Mohamadi, F.; Richards, N. G. J.; Guida, W. C.; Liskamp, R.; Caufield, C.; Chang, G.; Hendrickson, T.; Still, W. C. J. Comput. Chem. 1990, 11, 440.
42. This interpretation is supported by computational analyses (ref 20), which revealed only moderate energy increases for the following conformational perturbations relative to lowest energy 19 (cf. Figure 2): front-to-back rotations of the imidazole, cyanophenyl rings and back-to-front rotation of the chlorophenyl ring (1.66 kcal/mol); axial - equatorial isomerization (2.94 kcal/mol).
43. An alternative conformation of 13 with the carbonyl projected in the opposite direction relative to 19 is the enantiomer of lowest energy 13.
44. For assay conditions, see: Graham, S. L.; deSolms, S. J.; Giuliani, E. A.; Kohl, N. E.; Mosser, S. D.; Oliff, A. I.; Pompliano, D. L.; Rands, E.; Breslin, M. J.; Deanna, A. A.; Garsky, V. M.; Scholz, T. H.; Gibbs, J. B.; Smith, R. L. J. Med. Chem. 1994, 37, 725.